Comparative Pharmacology
Head-to-head clinical analysis: ARALEN HYDROCHLORIDE versus MEFLOQUINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARALEN HYDROCHLORIDE versus MEFLOQUINE HYDROCHLORIDE.
ARALEN HYDROCHLORIDE vs MEFLOQUINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as lysosomes and food vacuoles of malaria parasites, raising pH and inhibiting hemozoin polymerization, which leads to toxic heme accumulation and parasite death. It also has anti-inflammatory and immunomodulatory effects by inhibiting TLR signaling and cytokine production.
Mefloquine is a quinoline antimalarial agent that acts as a blood schizontocide. Its exact mechanism is unknown but is thought to involve forming toxic heme complexes or inhibiting heme polymerase, leading to parasite death.
Chloroquine phosphate 500 mg (300 mg base) orally once weekly for prophylaxis; 600 mg base (1 g phosphate) orally initially, followed by 300 mg base (500 mg phosphate) at 6, 24, and 48 hours for treatment of malaria.
250 mg (1 tablet) orally once weekly for prophylaxis; 1250 mg (5 tablets) as a single oral dose for treatment of uncomplicated malaria.
None Documented
None Documented
48-72 hours (terminal elimination half-life); prolonged to weeks with chronic dosing due to extensive tissue accumulation, especially in the liver, spleen, and melanin-containing tissues.
~2-4 weeks (terminal half-life); clinical context: long half-life allows weekly dosing for prophylaxis, but accumulation can occur with repeated doses.
Renal (~70% unchanged), with 10-20% in feces; biliary elimination is minor.
~83% (fecal/biliary), ~9% (renal unchanged), ~2.5% (renal as metabolite).
Category C
Category A/B
Antimalarial
Antimalarial